Related Experiment Video
Updated: May 16, 2026
03:42
Growing Desmoplastic Three-Dimensional Pancreatic Cancer Spheroids from Co-Culture
Published on: September 27, 2024
Targeting the αvβ5 Integrin Modifies the TGFβ-Rich Tumor Microenvironment of Pancreatic Cancer
Kodai Suzuki1, Yuki Kunisada1, Yukihito Kuroda1
1Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Cancer Research
|May 14, 2026
Summary
A novel peptide therapy targeting alpha-v integrin and neuropilin-1 (NRP-1) effectively remodels the pancreatic cancer tumor microenvironment (TME). This approach inhibits regulatory T cells (Tregs) and enhances anti-tumor immunity, improving immunotherapy outcomes.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits a complex, therapy-resistant tumor microenvironment (TME).
- The TME is characterized by desmoplasia, poor perfusion, and immunosuppression, driven by factors like transforming growth factor-beta (TGF-β).
- Regulatory T cells (Tregs) expressing alpha-v integrin and neuropilin-1 (NRP-1) contribute to immune suppression in PDAC.
Purpose of the Study:
- To investigate the therapeutic potential of a dual-targeting peptide (iRGD) that binds to alpha-v integrin and NRP-1.
- To determine if iRGD can reverse TME-associated features and enhance anti-tumor immunity in PDAC.
- To elucidate the mechanism by which iRGD affects TGF-β signaling and Treg populations.
Main Methods:
- Administration of iRGD peptide in a PDAC model.
- Analysis of TME components, including integrin and NRP-1 expression on tumor cells, fibroblasts, and Tregs.
- Assessment of TGF-β activation, Treg depletion, vascular perfusion, stromal density, and CD8+ T cell infiltration.
- Combination therapy with iRGD and immune checkpoint blockade.
Main Results:
- iRGD peptide inhibited TGF-β activation mediated by alpha-v beta-5 (αvβ5) integrin within the TME.
- Systemic iRGD therapy depleted αvβ5+ Tregs and reduced TGF-β signaling crucial for Treg maintenance.
- NRP-1-dependent tumor penetration was essential for iRGD's efficacy.
- iRGD treatment improved vascular patency, reduced stromal fibers, and increased CD8+ T cell infiltration.
- Combination therapy with iRGD and immune checkpoint blockade demonstrated enhanced anti-tumor effects.
Conclusions:
- Targeting αvβ5 integrin with ligands like iRGD can reprogram the PDAC TME.
- iRGD therapy shows promise in overcoming immune suppression and enhancing immunotherapy efficacy.
- This strategy offers a potential new avenue for treating PDAC and other desmoplastic tumors.
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...